• Age-related macular degeneration (AMD) is a progressive chronic disease of the central retina accounting for 8.7% of all blindness worldwide1.
• Early AMD patients exhibit moderate to severe impairment of dark adaptation (DA) even in the absence of visual acuity loss4–6.
• A test to probe rod function in dark adaptation can be used as a clinical outcome measure in studies tracking the progression of AMD, or more practically, a diagnostic tool targeting the identification of early AMD4.
• A patient’s rod function can be easily examined with Heru’s dark adaptation test which is billable to insurance (CPT 92284) and co-billable with visual fields, OCT and/or office visits.
Take Advantage of the ADA Tax Credit While Transforming Your Practice In the rapidly evolving field of optometry, technological advancements are continuously…
Heru’s automated diagnostics, efficiency, and accuracy help optometrists focus on what matters most—exceptional care. The optometrist’s time with the patient…
The eye care industry is facing a crisis — a growing patient population and a declining number of eye care…
With rising patient volumes, decreasing reimbursements, and a shortage of care providers, automation and digitization have become essential to prevent…
Heru Wins Prestigious CES Innovation Award for 2nd Consecutive Year with Expanded, Multimodal Platform MIAMI, FL (November 17, 2022) — Today,…
Heru Continues to Revolutionize Vision Care, Surpassing Clinical Milestone of 100,000 Eyes Examined MIAMI--November 14, 2022, Heru Inc. announced that…